538 Stock Overview
Engages in the pharmaceutical business in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Yunnan Baiyao Group Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥52.88 |
| 52 Week High | CN¥58.00 |
| 52 Week Low | CN¥44.88 |
| Beta | 0.46 |
| 1 Month Change | -7.63% |
| 3 Month Change | 4.73% |
| 1 Year Change | -1.03% |
| 3 Year Change | -41.83% |
| 5 Year Change | -0.41% |
| Change since IPO | 13,457.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 538 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.9% | -2.0% | -1.5% |
| 1Y | -1.0% | -13.0% | -11.8% |
Return vs Industry: 000538 exceeded the CN Pharmaceuticals industry which returned -13% over the past year.
Return vs Market: 000538 exceeded the CN Market which returned -11.8% over the past year.
Price Volatility
| 538 volatility | |
|---|---|
| 538 Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 000538 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000538's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1902 | 8,834 | Ming Dong | www.yunnanbaiyao.com.cn |
Yunnan Baiyao Group Co.,Ltd engages in the pharmaceutical business in China and internationally. It provides health products, drugs, medical instruments, and Chinese medicine resources. Yunnan Baiyao Group Co., Ltd.
Yunnan Baiyao Group Co.,Ltd Fundamentals Summary
| 538 fundamental statistics | |
|---|---|
| Market cap | CN¥94.35b |
| Earnings (TTM) | CN¥4.28b |
| Revenue (TTM) | CN¥39.37b |
22.1x
P/E Ratio2.4x
P/S RatioIs 538 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 538 income statement (TTM) | |
|---|---|
| Revenue | CN¥39.37b |
| Cost of Revenue | CN¥28.67b |
| Gross Profit | CN¥10.70b |
| Other Expenses | CN¥6.42b |
| Earnings | CN¥4.28b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.40 |
| Gross Margin | 27.18% |
| Net Profit Margin | 10.86% |
| Debt/Equity Ratio | 4.1% |
How did 538 perform over the long term?
See historical performance and comparison